Zobrazeno 1 - 10
of 940
pro vyhledávání: '"Jesús-F San Miguel"'
Autor:
Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén Iñigo, Javier de la Rubia, Ana-Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T Hernández, Javier López-Jiménez, Marta Reinoso, Aránzazu García-Mateo, Enrique M Ocio, Joan Bladé, Juan-José Lahuerta, María-Teresa Cedena, Bruno Paiva, Jesús F San Miguel, María-Victoria Mateos
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore
Externí odkaz:
https://doaj.org/article/c81a444b8f6e434cb89c96b45ea2aec6
Autor:
Cirino Botta, Cristina Perez, Marta Larrayoz, Noemi Puig, Maria-Teresa Cedena, Rosalinda Termini, Ibai Goicoechea, Sara Rodriguez, Aintzane Zabaleta, Aitziber Lopez, Sarai Sarvide, Laura Blanco, Daniele M. Papetti, Marco S. Nobile, Daniela Besozzi, Massimo Gentile, Pierpaolo Correale, Sergio Siragusa, Albert Oriol, Maria Esther González-Garcia, Anna Sureda, Felipe de Arriba, Rafael Rios Tamayo, Jose-Maria Moraleda, Mercedes Gironella, Miguel T. Hernandez, Joan Bargay, Luis Palomera, Albert Pérez-Montaña, Hartmut Goldschmidt, Hervé Avet-Loiseau, Aldo Roccaro, Alberto Orfao, Joaquin Martinez-Lopez, Laura Rosiñol, Juan-José Lahuerta, Joan Blade, Maria-Victoria Mateos, Jesús F. San-Miguel, Jose-Angel Martinez Climent, Bruno Paiva, the Programa Para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) cooperative group, the iMMunocell study group
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple
Externí odkaz:
https://doaj.org/article/2de8f8a904e64dd0bd9521c3f7eaa173
Autor:
Verónica González-Calle, Paula Rodríguez-Otero, Anna Sureda, Felipe de Arriba, Marta Reinoso, Paz Ribas, Ana Pilar González-Rodríguez, Yolanda González, Albert Oriol, Joaquín Martínez-López, Marta Sonia González, Miguel T. Hernández, Maialen Sirvent, Teresa Cedena, Noemí Puig, Bruno Paiva, Joan Bladé, Juan José Lahuerta, Jesús F. San-Miguel, María-Victoria Mateos
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-
Externí odkaz:
https://doaj.org/article/ee8847a91f344d7fa309aa58a2634a3b
Autor:
Ignacio J. Cardona-Benavides, Irena Misiewicz-Krzeminska, Elizabeta A. Rojas, Cristina De Ramón, Antonio Sanz-Solas, Isabel Isidro, Dalia Quwaider, Aida M. López-Guerrero, Myriam Cuadrado, María-José Calasanz, Laura Rosiñol, Joaquín Martínez-López, Jesús F. San Miguel, María-Victoria Mateos, Luis A. Corchete, Norma C. Gutiérrez
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Upregulation of a cyclin D gene determined by expression microarrays is an almost universal event in multiple myeloma (MM), but this finding has not been properly confirmed at the protein level. For this reason, we carried out a quantitative analysis
Externí odkaz:
https://doaj.org/article/d2fb4d2c2d1d4ba0898028202a445ac2
Autor:
Borja Puertas, Verónica González-Calle, Anna Sureda, María José Moreno, Albert Oriol, Esther González, Laura Rosiñol, Jordi López, Fernando Escalante, Joaquín Martínez-Lopez, Estrella Carrillo, Esther Clavero, Rafael Ríos-Tamayo, Beatriz Rey-Bua, Ana Pilar González-Rodríguez, Victoria Dourdil, Felipe de Arriba, Sonia González, Jaime Pérez-de-Oteyza, Miguel T. Hernández, Aránzazu García-Mateo, Joan Bargay, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel, Enrique M. Ocio, María-Victoria Mateos
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m2, cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed/refr
Externí odkaz:
https://doaj.org/article/a973b16234c247c6bee670237e99afa7
Autor:
Cristina Encinas, José-Ángel Hernandez-Rivas, Albert Oriol, Laura Rosiñol, María-Jesús Blanchard, José-María Bellón, Ramón García-Sanz, Javier de la Rubia, Ana López de la Guía, Ana Jímenez-Ubieto, Isidro Jarque, Belén Iñigo, Victoria Dourdil, Felipe de Arriba, Clara Cuéllar Pérez-Ávila, Yolanda Gonzalez, Miguel-Teodoro Hernández, Joan Bargay, Miguel Granell, Paula Rodríguez-Otero, Maialen Silvent, Carmen Cabrera, Rafael Rios, Adrián Alegre, Mercedes Gironella, Marta-Sonia Gonzalez, Anna Sureda, Antonia Sampol, Enrique M. Ocio, Isabel Krsnik, Antonio García, Aránzazu García-Mateo, Joan-Alfons Soler, Jesús Martín, José-María Arguiñano, María-Victoria Mateos, Joan Bladé, Jesús F. San-Miguel, Juan-José Lahuerta, Joaquín Martínez-López, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-8 (2022)
Abstract Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would
Externí odkaz:
https://doaj.org/article/fcb4c3d2e7254e4d93afeee7eb8db18a
Autor:
Sara Villar, Beñat Ariceta, Xabier Agirre, Aura Daniela Urribarri, Rosa Ayala, David Martínez-Cuadrón, Juan Miguel Bergua, Susana Vives, Lorenzo Algarra, Mar Tormo, Pilar Martínez, Josefina Serrano, Catia Simoes, Pilar Herrera, Maria José Calasanz, Ana Alfonso-Piérola, Bruno Paiva, Joaquín Martínez-López, Jesús F. San Miguel, Felipe Prósper, Pau Montesinos
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with a five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML pati
Externí odkaz:
https://doaj.org/article/3518c66232c441da81dbca6328896425
Autor:
Noemi Puig, Miguel T. Hernández, Laura Rosiñol, Esther González, Felipe de Arriba, Albert Oriol, Verónica González-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella, Rafael Ríos, Ricarda García-Sánchez, José M. Arguiñano, Adrián Alegre, Jesús Martín, Norma. C. Gutiérrez, María J. Calasanz, María L. Martín, María del Carmen Couto, María Casanova, Mario Arnao, Ernesto Pérez-Persona, Sebastián Garzón, Marta S. González, Guillermo Martín-Sánchez, Enrique M. Ocio, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana I. Teruel, María Cortés-Rodríguez, Bruno Paiva, M. Teresa Cedena, Jesús F. San-Miguel, Juan J. Lahuerta, Joan Bladé, Ruben Niesvizky, María-Victoria Mateos
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
Abstract Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 p
Externí odkaz:
https://doaj.org/article/fb9a610fa208459ba3fc58d65716e220
Autor:
Leire Burgos, Noemi Puig, Maria-Teresa Cedena, María-Victoria Mateos, Juan José Lahuerta, Bruno Paiva, Jesús F. San-Miguel
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-8 (2020)
Abstract The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most
Externí odkaz:
https://doaj.org/article/64ad9cf505d74164ad353558e6739939
Autor:
Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos, Norma C. Gutiérrez, Mercedes Garayoa, Enrique M. Ocio
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as the
Externí odkaz:
https://doaj.org/article/bfebf6dd497c42b797a071d86cc0e1d4